Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VER-027
- Development stage
- Preclinical
- Lead developer
- Vernagen
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
VER-027 is a preclinical-stage mRNA vaccine developed by Vernagen, in partnership with Emory University, for the prevention of respiratory syncytial virus (RSV) infection. The vaccine is designed to encode the stabilized prefusion conformation of the fusion (F) glycoprotein from both RSV subgroup A and RSV subgroup B. Formulated with lipid nanoparticles (LNPs) for delivery, VER-027 induces robust neutralizing antibody responses and activates RSV-specific cellular immunity, including CD8+ T cells. Preclinical studies in animal models have demonstrated complete protection against challenge with either RSV subgroup. Vernagen is supported by its parent company, ST PHARM, which provides contract development and manufacturing services.
- Other names
- messenger ribonucleic acid respiratory syncytial virus A/B vaccine
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on VER-027.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VER-027.